BOSTON & SHREVEPORT, La.--(BUSINESS WIRE)--<a target"_blank" href"http://cts.businesswire.com/ct/CT?idsmartlink&urlhttp%3A%2F%2Fwww.emberaneuro.com&esheet51698580&newsitemid20171013005072&lanen-US&anchorEmberaNeuroTherapeutics%2CInc.&index1&md576457b4b297e4348b6a6f7e6dec08767" rel"nofollow... Source: BioSpace
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x430-google.jpg" NAME"Big Pharmas are Poaching Top Talent From Tech Giants Like Google and LinkedIn" ALT"Big Pharmas are Poaching Top Talent From Tech Giants Like Google and LinkedIn"October 13, 2017By…
- Leading Experts to Discuss Clinical Programs in Primary Liver Cancer and Ovarian Cancer LAWRENCEVILLE, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology development company, today…
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x430-national-institutes-of-health.jpg" NAME"NIH Hooks Up With 11 Top Biopharmas for $215 Million Cancer Moonshot Deal" ALT"NIH Hooks Up With 11 Top Biopharmas for $215 Million Cancer Moonshot Deal"October 13, 2017By…
HOBOKEN, N.J.--(BUSINESS WIRE)--John Wiley and Sons, Inc. (NYSE: JWA) (NYSE: JWB), a global research and learning company, today announced that Ella Balagula has been named Wileys new Executive Vice President…
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-fda.jpg" NAME"Spark Therapeutics Jumps as FDA Panel Unanimously Backs Breakthrough Gene Therapy" ALT"Spark Therapeutics Jumps as FDA Panel Unanimously Backs Breakthrough Gene Therapy"October 13, 2017By Mark Terry, BioSpace... Source:…
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical (Vivasure) is pleased to announce the successful enrollment of the first patient in the Frontier IV clinical study, a non-randomized multicenter international trial, designed to expand…
In a new draft guidance, the FDA describes which abbreviated approval pathways are available for ANDAs and 505(b)(2) applications. Source: Drug Industry Daily
Developers of antiviral drugs for prophylaxis and treatment of respiratory syncytial virus should expose at least 100 adults in clinical trials ahead of pediatric studies, the FDA said in new…
Rigorous patient preference information should be part of the FDA’s process to determine risks and benefits of new products, Commissioner Scott Gottlieb said in a statement coinciding with the inaugural…